Shattuck Labs Q2 net loss $21.3M ($0.50/sh); cash $117.2M; SL-172154 trials advancing

Shattuck Labs, Inc.

2023-Q2 EPS reported -$0.99 revenue$257,000

Cash and investments $117.2M at June 30, 2023, down from $214.2M a year earlier; runway through end of 2024.
Net loss of $21.3M ($0.50 per share) for Q2 2023 vs. $27.4M ($0.65) in Q2 2022; R&D spend decreased to $18.2M.
Phase 1A PROC monotherapy data presented at ASCO 2023; 3 mg/kg dose selected for combination cohorts.
Enrollment completed in dose-escalation part of Phase 1A/B for SL-172154 in AML/HR-MDS; initial combo data expected Q4 2023.
GADLEN platform: second NHP toxicology study showed inferior B-cell depletion; no IND planned until resolved.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Shattuck Labs, Inc. reported financial results for quarter ended June 30, 2023.

Period: quarter ended June 30, 2023
Result: reported results

Exact text from the filing

On August 10, 2023, Shattuck Labs, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Shattuck Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001680367-23-000049

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.